• Loading stock data...
Est. 2004

LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

Saturday 09/23/2017
SMALL CAP MARKET NEWS

We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.


LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

Finance

  • 3:03 PM

    VANCOUVER, BRITISH COLUMBIA, GPHOF, GPH, –(Marketwired – Jan 19, 2016) – Graphite One Resources Inc. (TSX VENTURE:GPH)(OTCQX:GPHOF) (“Graphite One” or the “Company”) is pleased to announce that it has completed and closed on the first tranche of its $600,000 non-brokered private placement offering (the “Offering”) as originally announced in the December 2, 2015 press release. Pursuant to this closing, the Company has issued 4,823,222 Units (the “Units”) at a price of $0.09 per Unit for a total of $434,090. Each

    Read more
  • 4:44 PM

    Jan 14, 2016, MSLP,  OTC Disclosure & News Service – MusclePharm Corporation (OTCQB: MSLP) (“MusclePharm” or the “Company”), a scientifically-driven, performance lifestyle sports nutrition company, today announced the completion of a financing agreement with Prestige Capital Corporation (“Prestige Capital”) in the initial amount of $10 million. The financing agreement is a major step towards strengthening the Company’s financial position. The agreement with Prestige Capital allows the Company to use its receivables to finance up to a total of $10 million. The Company

    Read more
  • 2:59 PM

    http://www.publicwire.comNuvilex Retains TD2 to Conduct Preclinical and Clinical Studies SILVER SPRING, Apr 01, 2014 (GLOBE NEWSWIRE via COMTEX) — Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that it has signed a Master Services Agreement with Translational Drug Development (TD2) pursuant to which TD2 will conduct preclinical and clinical studies in support of the development of Nuvilex’s pancreatic cancer and other treatments utilizing Cell-in-a-Boxtechnology. “The Nuvilex team

    Read more
Public Wire Banner